AB&B BIO-TECH-B (02627) surged over 7%. As of press time, the stock climbed 7.25% to HK$50.6, with a turnover of HK$136.446 million. On the news front, AB&B BIO-TECH-B announced that the Investigational New Drug (IND) application for the Group's self-developed recombinant respiratory syncytial virus vaccine (CHO cell) (adjuvanted) has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration. Additionally, the IND application for this vaccine in the United States has also been approved by the U.S. Food and Drug Administration (FDA). The announcement noted that the Group's recombinant respiratory syncytial virus vaccine (CHO cell) (adjuvanted) is developed using CHO cells and can express modified pre-F protein. Through extensive screening, the Group has obtained high-yield monoclonal cell lines capable of stably expressing pre-F protein. In the Group's preclinical studies, it demonstrated higher pre-F expression levels, better thermal stability, and superior immunogenicity compared to marketed recombinant RSV vaccines.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.